Lu Wang
Impact in
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
Papers in
-
- Circular RNAs in diseases 6
- RNA modifications and cancer 5
- Natural product bioactivities and synthesis 5
- Oncology 28
- Cytokine Signaling Pathways and Interactions 9
- Co-authors
- Shuwen Yu (11 shared papers)Min Jiang (2 shared papers)Qi Long Lu (1 shared paper)Shuangshuang Li (1 shared paper)Hong Qiu (1 shared paper)Ping Peng (1 shared paper)Qianqian Yu (1 shared paper)Xianglin Yuan (1 shared paper)
- Journals
- Biomedicine & Pharmacotherapy (8 papers)Scientific Reports (3 papers)Frontiers in Oncology (3 papers)Acta Pharmaceutica Sinica B (2 papers)Chemico-Biological Interactions (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Lu Wang
114 papers receiving 3.5k citations
Lu Wang's Hit Papers
Peers
Comparison fields: 5 of 140
- Cancer Research 672
- Oncology 783
- Biochemistry 171
- Immunology 553
- Molecular Biology 1.4k
Countries citing papers authored by Lu Wang
This map shows the geographic impact of Lu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Wang more than expected).
Fields of papers citing papers by Lu Wang
This network shows the impact of papers produced by Lu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Wang. The network helps show where Lu Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 229 | |
| 2 | PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages Hit paper breakdown → | 2022 | 173 |
| 3 | Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy Hit paper breakdown → | 2024 | 169 |
| 4 | 2012 | 156 | |
| 5 | 2016 | 136 | |
| 6 | 2007 | 132 | |
| 7 | 2020 | 112 | |
| 8 | 2019 | 105 | |
| 9 | 2020 | 85 | |
| 10 | 2014 | 83 | |
| 11 | 2022 | 82 | |
| 12 | 2021 | 81 | |
| 13 | 2006 | 76 | |
| 14 | 2017 | 72 | |
| 15 | 2007 | 71 | |
| 16 | 2017 | 69 | |
| 17 | 2020 | 66 | |
| 18 | 2022 | 66 | |
| 19 | 2015 | 62 | |
| 20 | 2015 | 55 |
About Lu Wang
Lu Wang is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Surgery, having authored 122 papers that have together received 3.5k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (13 papers), Cytokine Signaling Pathways and Interactions (9 papers), Phytochemistry and Biological Activities (7 papers), Circular RNAs in diseases (6 papers), Immune Cell Function and Interaction (6 papers), MicroRNA in disease regulation (6 papers), RNA modifications and cancer (5 papers) and Natural product bioactivities and synthesis (5 papers). The work is most often cited by research in Cancer Research (672 citations), Oncology (783 citations), Biochemistry (171 citations), Immunology (553 citations) and Molecular Biology (1.4k citations). Lu Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Shuwen Yu, Min Jiang, Qi Long Lu, Shuangshuang Li, Hong Qiu, Ping Peng, Qianqian Yu, Xianglin Yuan, Ben Zhao and Li Sun. Their work appears in journals such as Biomedicine & Pharmacotherapy, Scientific Reports, Frontiers in Oncology, Acta Pharmaceutica Sinica B and Chemico-Biological Interactions.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.